Hyderabad: In a lift for Hyderabad-based Natco Pharma, a division bench of the Delhi excessive court docket has dismissed a patent infringement enchantment over insecticide Chlorantraniliprole (CTPR) filed by FMC Company and its subsidiaries. In accordance with Natco, the present measurement of the marketplace for CTPR containing merchandise is pegged at over Rs 2,000 crore.
“…double bench of the excessive court docket of Delhi has dismissed an enchantment filed by FMC Company, FMC Singapore and FMC India and has upheld prima facie the judgment of the only choose that the Natco Chlorantraniliprole (CTPR) course of doesn’t infringe FMC’s Indian Patent 298645,” Natco Pharma mentioned in a regulatory submitting to the bourses on Monday.
The choice comes a few months after a single bench of the court docket gave Natco the nod to roll out insecticide CTPR and its formulations within the Indian market. The choose dominated that Natco’s course of didn’t infringe on FMC’s patent.
The US-based agricultural sciences participant FMC Company had sued Natco within the Delhi excessive court docket in Could citing infringement of a course of patent to fabricate CTPR, which is about to run out on December 6, 2025.
Following the court docket’s approval, the corporate had on September 24, introduced the rollout of CTPR 18.5% SC beneath the Natgen model within the Indian market.
The Hyderabad-based pharma firm, which forayed into agri-chemicals enterprise in early 2019, was the primary firm in India to obtain approval from the Central Insecticide Board & Registration Committee (CIB&RC) in January 2021 for the indigenous manufacture of CTPR technical 93%, the corporate had mentioned early final yr.
Natco Pharma has been embroiled in a authorized battle with FMC Company in Indian courts since 2019.
“…double bench of the excessive court docket of Delhi has dismissed an enchantment filed by FMC Company, FMC Singapore and FMC India and has upheld prima facie the judgment of the only choose that the Natco Chlorantraniliprole (CTPR) course of doesn’t infringe FMC’s Indian Patent 298645,” Natco Pharma mentioned in a regulatory submitting to the bourses on Monday.
The choice comes a few months after a single bench of the court docket gave Natco the nod to roll out insecticide CTPR and its formulations within the Indian market. The choose dominated that Natco’s course of didn’t infringe on FMC’s patent.
The US-based agricultural sciences participant FMC Company had sued Natco within the Delhi excessive court docket in Could citing infringement of a course of patent to fabricate CTPR, which is about to run out on December 6, 2025.
Following the court docket’s approval, the corporate had on September 24, introduced the rollout of CTPR 18.5% SC beneath the Natgen model within the Indian market.
The Hyderabad-based pharma firm, which forayed into agri-chemicals enterprise in early 2019, was the primary firm in India to obtain approval from the Central Insecticide Board & Registration Committee (CIB&RC) in January 2021 for the indigenous manufacture of CTPR technical 93%, the corporate had mentioned early final yr.
Natco Pharma has been embroiled in a authorized battle with FMC Company in Indian courts since 2019.
